Atrys Health
Atrys Health
ATRY
BME
3.21
EUR
-0.31%
About
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies.
It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 16.3K |
| Three Month Average Volume | 434.2K |
| High Low | |
| Fifty-Two Week High | 4.92 EUR |
| Fifty-Two Week Low | 2.77 EUR |
| Fifty-Two Week High Date | 04 Sep 2023 |
| Fifty-Two Week Low Date | 02 May 2024 |
| Price and Volume | |
| Current Price | 3.4 EUR |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.68% |
| Thirteen Week Relative Price Change | -14.74% |
| Twenty-Six Week Relative Price Change | -3.19% |
| Fifty-Two Week Relative Price Change | -41.67% |
| Year-to-Date Relative Price Change | -17.92% |
| Price Change | |
| One Day Price Change | -2.30% |
| Thirteen Week Price Change | -14.14% |
| Twenty-Six Week Price Change | 9.68% |
| Five Day Price Change | -5.29% |
| Fifty-Two Week Price Change | -30.04% |
| Year-to-Date Price Change | -7.36% |
| Month-to-Date Price Change | -0.29% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.8174 EUR |
| Book Value Per Share (Most Recent Quarter) | 3.57129 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -2.11516 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -2.15194 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 0.41554 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.65885 EUR |
| Revenue Per Share (Trailing Twelve Months) | 2.51203 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.40163 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.44894 EUR |
| Normalized (Last Fiscal Year) | -0.40398 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.40163 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.44894 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -0.60137 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -0.51438 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.59812 EUR |
| Cash Per Share (Most Recent Quarter) | 0.30342 EUR |
| Cash Flow Per Share (Last Fiscal Year) | 0.03486 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -0.05895 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.32764 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -11 |
| Cash Flow Revenue (Trailing Twelve Months) | -13 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -18.10% |
| Pretax Margin (Last Fiscal Year) | -16.72% |
| Pretax Margin (5 Year) | -16.40% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 70.33% |
| Gross Margin (Trailing Twelve Months) | 66.90% |
| Gross Margin (5 Year) | 76.84% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -0.44% |
| Operating Margin (Trailing Twelve Months) | -3.74% |
| Operating Margin (5 Year) | -5.04% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -15.26% |
| Net Profit Margin (Trailing Twelve Months) | -18.01% |
| Net Profit Margin (5 Year) | -15.56% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 25.60% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 5.05% |
| Revenue Growth (3 Year) | 94.22% |
| Revenue Change (Trailing Twelve Months) | 12.33% |
| Revenue Per Share Growth | 48.23% |
| Revenue Growth (5 Year) | 85.86% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 41.88% |
| Total Debt (5 Year) | 90.96% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -6.41% |
| EPS Change (Trailing Twelve Months) | 12.53% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | 73.55% |
| EBITDA (5 Year Interim) | 64.50% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 227.3M |
| Net Debt (Last Fiscal Year) | 149.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 60 |
| Long Term Debt to Equity (Most Recent Quarter) | 73 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -14,241,000 |
| Free Cash Flow (Trailing Twelve Months) | -24,883,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 0 |
| Net Interest Coverage (Trailing Twelve Months) | 0 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 67 |
| Total Debt to Equity (Most Recent Quarter) | 92 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -4.61% |
| Return on Assets (Trailing Twelve Months) | -5.29% |
| Return on Assets (5 Year) | -4.38% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -9.72% |
| Return on Equity (Trailing Twelve Months) | -11.57% |
| Return on Equity (5 Year) | -9.22% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -5.45% |
| Return on Investment (Trailing Twelve Months) | -6.29% |
| Return on Investment (5 Year) | -5.07% |